Search

Your search keyword '"Levin, A. D."' showing total 3,372 results
Start Over Author "Levin, A. D."
3,372 results on '"Levin, A. D."'

251. New Pay Versus Performance Disclosure To Be Required In Upcoming Proxy Statements

Author

Levin, Lawrence D.

Subjects
United States. Securities and Exchange Commission -- Powers and duties, Business, international
Abstract

On August 25, the Securities and Exchange Commission (SEC) adopted final rules which will require disclosure of a comparison of the company's performance to the compensation actually paid to the [...]

Published
2022

252. Examining the Relationship between Educational Outcomes and Gaps in Funding: An Extension of the New York Adequacy Study

Author

Chambers, Jay G., Levin, Jesse D., and Parrish, Thomas B.

Abstract

In 1993, the Campaign for Fiscal Equity (CFE) challenged New York State's school financing system on the grounds that it failed to provide students sufficient opportunity for a sound basic education in New York City. CFE prevailed in 2003, after the case went before the New York Court of Appeals, and the state's funding system was determined to be unconstitutional and ordered to be altered to ensure "adequate" funding. The final decision decreed that before any remediation take place, an objective study be conducted to determine how much it would cost to provide an "adequate" education for all public school students in the state, on which this article is based. Although a professional judgment approach forms the centerpiece of the work, components of the analysis draw on other methodological tools (i.e., public engagement, expert panels, and successful schools) to further support the results. We find that for a majority of districts significantly higher levels of spending are required if the state wishes to provide a sound basic education to all public school students. Furthermore, the results show a clear negative relationship between the district-level shortfall in spending and educational outcomes across virtually all student subpopulations.

Published
2006
Full Text
View/download PDF

253. Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

Author

Dimopoulos, MA, Schjesvold, F, Doronin, V, Vinogradova, O, Quach, H, Leleu, X, Montes, YG, Ramasamy, K, Pompa, A, Levin, M-D, Lee, C, Mellqvist, UH, Fenk, R, Demarquette, H, Sati, H, Vorog, A, Labotka, R, Du, J, Darif, M, Kumar, S, Dimopoulos, MA, Schjesvold, F, Doronin, V, Vinogradova, O, Quach, H, Leleu, X, Montes, YG, Ramasamy, K, Pompa, A, Levin, M-D, Lee, C, Mellqvist, UH, Fenk, R, Demarquette, H, Sati, H, Vorog, A, Labotka, R, Du, J, Darif, M, and Kumar, S

Abstract

Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As patients age, they become less tolerant to treatment, requiring convenient/tolerable/lenalidomide-free options. Carfilzomib and/or bortezomib-exposed/intolerant, lenalidomide-refractory MM patients with ≥2 prior lines of therapy were randomized 3:2 to ixazomib-dexamethasone (ixa-dex) (n = 73) or pomalidomide-dexamethasone (pom-dex) (n = 49) until progression/toxicity. Median progression-free survival (mPFS) was 7.1 vs 4.8 months with ixa-dex vs pom-dex (HR 0.847, 95% CI 0.535-1.341, P = 0.477; median follow-up: 15.3 vs 17.3 months); there was no statistically significant difference between arms. In patients with 2 and ≥3 prior lines of therapy, respectively, mPFS was 11.0 vs 5.7 months (HR 1.083, 95% CI 0.547-2.144) and 5.7 vs 3.7 months (HR 0.686, 95% CI 0.368-1.279). Among ixa-dex vs pom-dex patients, 69% vs 81% had Grade ≥3 treatment-emergent adverse events (TEAEs), 51% vs 53% had serious TEAEs, 39% vs 36% had TEAEs leading to drug discontinuation, 44% vs 32% had TEAEs leading to dose reduction, and 13% vs 13% died on study. Quality of life was similar between arms and maintained during treatment. Ixa-dex represents an important lenalidomide-free, oral option for this heavily pretreated, lenalidomide-refractory, proteasome inhibitor-exposed population.Trial registration: ClinicalTrials.gov number, NCT03170882.

Published
2022

254. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, D., Milic, N., Chatzikonstantinou, T., Scarfo, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuellar-Garcia, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., Efstathopoulou, M., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Lopez-Garcia, A., Garcia-Marco, J. A., Garcia-Serra, R., Gentile, Marino, Gimeno, E., da Silva, M. G., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernandez-Rivas, J. A., Herold, T., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, O. B., Kalicinska, E., Kater, A. P., Kersting, S., Koren-Michowitz, M., Labrador, J., Lad, D., Laurenti, Luca, Fresa, Alberto, Levin, M. -D., Mayor Bastida, C., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mihaljevic, B., Milosevic, I., Miras, F., Morawska, M., Motta, M., Munir, T., Murru, R., Nunes, R., Olivieri, J., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Reda, G., Rigolin, G. M., Shrestha, A., Simkovic, M., Smirnova, S., Spacek, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Te Raa, D., Tomic, K., Tonino, S., Trentin, L., Van Der Spek, E., van Gelder, M., Varettoni, M., Visentin, A., Vitale, C., Vukovic, Vladimir, Wasik-Szczepanek, E., Wrobel, T., Segundo, L. Y. S., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Carrier, M., Ghia, P., Stamatopoulos, K., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Fresa A., Vukovic V. (ORCID:0000-0002-9561-7825), Foa R., Antic, D., Milic, N., Chatzikonstantinou, T., Scarfo, L., Otasevic, V., Rajovic, N., Allsup, D., Alonso Cabrero, A., Andres, M., Baile Gonzales, M., Capasso, A., Collado, R., Cordoba, R., Cuellar-Garcia, C., Correa, J. G., De Paoli, L., De Paolis, M. R., Del Poeta, G., Dimou, M., Doubek, M., Efstathopoulou, M., El-Ashwah, S., Enrico, A., Espinet, B., Farina, L., Ferrari, A., Foglietta, M., Lopez-Garcia, A., Garcia-Marco, J. A., Garcia-Serra, R., Gentile, Marino, Gimeno, E., da Silva, M. G., Gutwein, O., Hakobyan, Y. K., Herishanu, Y., Hernandez-Rivas, J. A., Herold, T., Itchaki, G., Jaksic, O., Janssens, A., Kalashnikova, O. B., Kalicinska, E., Kater, A. P., Kersting, S., Koren-Michowitz, M., Labrador, J., Lad, D., Laurenti, Luca, Fresa, Alberto, Levin, M. -D., Mayor Bastida, C., Malerba, L., Marasca, R., Marchetti, M., Marquet, J., Mihaljevic, B., Milosevic, I., Miras, F., Morawska, M., Motta, M., Munir, T., Murru, R., Nunes, R., Olivieri, J., Pavlovsky, M. A., Piskunova, I., Popov, V. M., Quaglia, F. M., Quaresmini, G., Reda, G., Rigolin, G. M., Shrestha, A., Simkovic, M., Smirnova, S., Spacek, M., Sportoletti, P., Stanca, O., Stavroyianni, N., Te Raa, D., Tomic, K., Tonino, S., Trentin, L., Van Der Spek, E., van Gelder, M., Varettoni, M., Visentin, A., Vitale, C., Vukovic, Vladimir, Wasik-Szczepanek, E., Wrobel, T., Segundo, L. Y. S., Yassin, M., Coscia, M., Rambaldi, A., Montserrat, E., Foa, Robin, Cuneo, A., Carrier, M., Ghia, P., Stamatopoulos, K., Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Fresa A., Vukovic V. (ORCID:0000-0002-9561-7825), and Foa R.

Abstract

Background: Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disease and treatment-related immune deficiency. The aim of this study was to assess the risk of thrombosis and bleeding in patients with CLL affected by severe COVID-19. Methods: This is a retrospective multicenter study conducted by ERIC, the European Research Initiative on CLL, including patients from 79 centers across 22 countries. Data collection was conducted between April and May 2021. The COVID-19 diagnosis was confirmed by the real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 on nasal or pharyngeal swabs. Severe cases of COVID-19 were defined by hospitalization and the need of oxygen or admission into ICU. Development and type of thrombotic events, presence and severity of bleeding complications were reported during treatment for COVID-19. Bleeding events were classified using ISTH definition. STROBE recommendations were used in order to enhance reporting. Results: A total of 793 patients from 79 centers were included in the study with 593 being hospitalized (74.8%). Among these, 511 were defined as having severe COVID: 162 were admitted to the ICU while 349 received oxygen supplementation outside the ICU. Most patients (90.5%) were receiving thromboprophylaxis. During COVID-19 treatment, 11.1% developed a thromboembolic event, while 5.0% experienced bleeding. Thrombosis developed in 21.6% of patients who were not receiving thromboprophylaxis, in contrast to 10.6% of patients who were on thromboprophylaxis. Bleeding episodes were more frequent in patients receiving intermediate/therapeutic versus prophylactic doses of low-molecular-weight heparin (LWMH) (8.1% vs. 3.8%, respectively) and in elderly. In multivariate analysis, peak D-dimer level and C-reactive protein to albumin ratio were poor prognostic factors for thrombosis occu

Published
2022

256. Theoretical Design of Organic Chromophores with Large Two-Photon Absorption Cross-Sections

Author

Albota, Marius, Beljonne, David, Brédas, Jean-Luc, Ehrlich, Jeffrey E., Fu, Jia-Ying, Heikal, Ahmed A., Hess, Samuel, Kogej, Thierry, Levin, Michael D., Marder, Seth R., McCordMaughon, Dianne, Perry, Joseph W., Röckel, Harald, Rumi, Mariacristina, Subramaniam, Girija, Webb, Watt W., Wu, Xiang-Li, Xu, Chris, Kajzar, François, editor, and Agranovich, M. Vladimir, editor

Published
2000
Full Text
View/download PDF

258. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Author

Ossenkoppele, Gert J., Stussi, Georg, Maertens, Johan, van Montfort, Kees, Biemond, Bart J., Breems, Dimitri, Ferrant, August, Graux, Carlos, de Greef, Georgine E., Halkes, C. J.M., Hoogendoorn, Mels, Hollestein, Rene M., Jongen-Lavrencic, Mojca, Levin, Mark D., van de Loosdrecht, Arjan A., van Marwijk Kooij, Marinus, van Norden, Yvette, Pabst, Thomas, Schouten, Harry C., Vellenga, Edo, Verhoef, Gregor E.G., de Weerdt, Okke, Wijermans, Pierre, Passweg, Jakob R., and Löwenberg, Bob

Published
2012
Full Text
View/download PDF

265. Elastin Insufficiency Confers Proximal and Distal Pulmonary Vasculopathy in Mice, Partially Remedied by the KATP Channel Opener Minoxidil: Considerations and Cautions for the Treatment of People With Williams-Beuren Syndrome

Author

Knutsen, Russell H., primary, Gober, Leah M., additional, Kronquist, Elise K., additional, Kaur, Maninder, additional, Donahue, Danielle R., additional, Springer, Danielle, additional, Yu, Zu Xi, additional, Chen, Marcus Y., additional, Fu, Yi-Ping, additional, Choobdar, Feri, additional, Nguyen, My-Le, additional, Osgood, Sharon, additional, Freeman, Joy L., additional, Raja, Neelam, additional, Levin, Mark D., additional, and Kozel, Beth A., additional

Published
2022
Full Text
View/download PDF

272. Introduction

Author

Levin, Michael, D.

Published
1993

274. Contributors

Author

Levin, Michael, D.

Published
1993

280. Preface

Author

Levin, Michael, D.

Published
1993

284. Front Matter

Author

Levin, Michael, D.

Published
1993

285. Additional file 2 of Sperm DNA methylation alterations from cannabis extract exposure are evident in offspring

Author

Schrott, Rose, Modliszewski, Jennifer L., Hawkey, Andrew B., Grenier, Carole, Holloway, Zade, Evans, Janequia, Pippen, Erica, Corcoran, David L., Levin, Edward D., and Murphy, Susan K.

Abstract

Additional file 2: Figure S2. Pyrosequencing validation of WGBS CpG sites. Bisulfite pyrosequencing of CpG sites initially identified via WGBS as significantly differentially methylated between late exposed sperm and controls for A Hoxb9; B Mettl11b; C Sycp3; D Cit; E Slit2; F Lrp1; G Cit; and early exposed and controls H Grin2a; I Syn3. CpG sites are identified as A-D on the x-axis, and the recorded methylation level is on the y-axis. Each point is an individual sperm. Black = controls, green = late exposed, blue = early exposed. *p < 0.05.

Published
2022
Full Text
View/download PDF

286. Additional file 1 of Sperm DNA methylation alterations from cannabis extract exposure are evident in offspring

Author

Schrott, Rose, Modliszewski, Jennifer L., Hawkey, Andrew B., Grenier, Carole, Holloway, Zade, Evans, Janequia, Pippen, Erica, Corcoran, David L., Levin, Edward D., and Murphy, Susan K.

Abstract

Additional file 1: Figure S1. Pyrosequencing Validation Curves. Defined mixtures of bisulfite modified fully methylated and unmethylated rat genomic DNAs were analyzed for linearity in ability to detect increasing amounts of methylation. X-axis, the input (expected) level of methylation, y-axis, the measured level of methylation. R2 and p-values values are indicated.

Published
2022
Full Text
View/download PDF

287. Additional file 3 of Sperm DNA methylation alterations from cannabis extract exposure are evident in offspring

Author

Schrott, Rose, Modliszewski, Jennifer L., Hawkey, Andrew B., Grenier, Carole, Holloway, Zade, Evans, Janequia, Pippen, Erica, Corcoran, David L., Levin, Edward D., and Murphy, Susan K.

Abstract

Additional file 3: Figure S3. Relationship between DNA methylation at CpG site 1 and gene expression for Mtss1l in the hippocampus. Relationship between DNA methylation and gene expression for Mtss1l in A all sexes combined; B males only; and C females only. Pearson correlation R square and p-values are reported. Control offspring = black with solid regression line; early exposed offspring = blue with dotted regression line.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results